What Is Therapeutic Plasma Exchange (TPE)?

Therapeutic Plasma Exchange (TPE) separates blood into plasma and cellular components, removes a prescribed plasma volume, then returns the blood cells with replacement fluid. The goal is rapid reduction of circulating substances such as autoantibodies, immune complexes, paraproteins, or toxins while replacement fluid maintains volume and, when needed, supplies plasma proteins.

TPE and plasmapheresis are related but not always identical terms

“Plasmapheresis” can broadly describe separating and collecting or removing plasma, including donation. TPE is a therapeutic large-volume exchange with clinical monitoring and replacement fluid. It is not plasma donation, dialysis, EBOO, or PRP.

Indications are disease-specific

The American Society for Apheresis (ASFA) categorizes uses by evidence and role in care. Examples with established roles include immune thrombotic thrombocytopenic purpura, Guillain–Barré syndrome, acute short-term treatment of myasthenia gravis, and symptomatic hyperviscosity from selected paraproteinemias. Exact timing, replacement fluid, exchange volume, and accompanying therapy differ by disease. ASFA categories are guideline recommendations—not “FDA approval” of a procedure for a diagnosis.

How treatment is performed

Centrifugal systems separate components by density; membrane systems filter plasma by size. A session commonly processes enough blood to exchange roughly one calculated plasma volume, but dose is prescribed by the treating service. Peripheral access may be possible; a central venous catheter adds infection, clot, bleeding, and mechanical risks.

Replacement and medication planning

Albumin is commonly used when protein replacement without clotting factors is appropriate. Donor plasma is essential for selected indications such as immune TTP and when coagulation-factor replacement is required. TPE can remove medications—especially recently administered, intravascular, highly protein-bound agents and some monoclonal antibodies—so drug timing must be coordinated.

Not a wellness detox

TPE removes plasma nonselectively, including beneficial immunoglobulins and coagulation proteins. Biomarker changes after exchange do not establish longer life or improved health in healthy people. Elective longevity use lacks an accepted schedule, validated clinical endpoint, and evidence that benefit outweighs procedural risk and cost.